ACARIX Stock Overview
A medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Acarix AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.42 |
52 Week High | SEK 0.60 |
52 Week Low | SEK 0.17 |
Beta | 1.4 |
11 Month Change | -14.29% |
3 Month Change | 40.94% |
1 Year Change | -17.65% |
33 Year Change | -71.54% |
5 Year Change | -91.70% |
Change since IPO | -97.42% |
Recent News & Updates
Recent updates
Will Acarix (STO:ACARIX) Spend Its Cash Wisely?
Jun 13Here's Why We're Watching Acarix's (STO:ACARIX) Cash Burn Situation
Jun 12We're Keeping An Eye On Acarix's (STO:ACARIX) Cash Burn Rate
Oct 27Will Acarix (STO:ACARIX) Spend Its Cash Wisely?
Jun 22Companies Like Acarix (STO:ACARIX) Are In A Position To Invest In Growth
Mar 04Shareholder Returns
ACARIX | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | -21.5% | -4.0% | -4.3% |
1Y | -17.6% | -0.002% | 12.6% |
Return vs Industry: ACARIX underperformed the Swedish Medical Equipment industry which returned -0% over the past year.
Return vs Market: ACARIX underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
ACARIX volatility | |
---|---|
ACARIX Average Weekly Movement | 11.1% |
Medical Equipment Industry Average Movement | 7.1% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ACARIX's share price has been volatile over the past 3 months.
Volatility Over Time: ACARIX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 14 | Aamir Mahmood | www.acarix.com |
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States.
Acarix AB (publ) Fundamentals Summary
ACARIX fundamental statistics | |
---|---|
Market cap | SEK 408.73m |
Earnings (TTM) | -SEK 76.29m |
Revenue (TTM) | SEK 5.84m |
70.0x
P/S Ratio-5.4x
P/E RatioIs ACARIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACARIX income statement (TTM) | |
---|---|
Revenue | SEK 5.84m |
Cost of Revenue | SEK 815.00k |
Gross Profit | SEK 5.02m |
Other Expenses | SEK 81.31m |
Earnings | -SEK 76.29m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
Earnings per share (EPS) | -0.078 |
Gross Margin | 86.04% |
Net Profit Margin | -1,306.56% |
Debt/Equity Ratio | 0% |
How did ACARIX perform over the long term?
See historical performance and comparison